Natera (Signatera)
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Signatera is a tumor-informed assay, meaning it is custom-built for each patient based on their unique tumor signature, offering higher sensitivity than generic 'tumor-naive' liquid biopsies.
Description Brand's website · 2026-10-04
Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. Its flagship oncology product, Signatera, is a personalized, tumor-informed molecular residual disease (MRD) test designed to detect cancer recurrence earlier than standard imaging.
Offerings
Core capabilities Brand's website · 2026-10-04
- Signatera (Oncology MRD)
- Panorama (NIPT)
- Horizon (Carrier Screening)
- Prospera (Organ Health)
Pricing Brand's website · 2026-10-04
Insurance-based/Enterprise Custom (Medical Billing)
Audience
Target industry Brand's website · 2026-10-04
Oncology, Reproductive Health, Nephrology, Transplant Medicine
Landscape
Competitors Brand's website · 2026-10-04
- Guardant Health (Guardant Reveal)
- Exact Sciences (Thrive)
- Foundation Medicine (FoundationOne Tracker)
- Grail (Galleri)
Is this your business?
The information above is publicly sourced — assembled by Optimly from Natera (Signatera)'s website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Natera (Signatera) across the index.
Claim Natera (Signatera) — free →Page last updated 2026-10-17.